These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 17728218

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Features of prostate cancers detected during a prevalence screening round. The Rotterdam experience.
    Van der Kwast TH, Postma R, Hoedemaeker RF, van Leenders GJ, Schröder FH.
    Can J Urol; 2005 Jun; 12 Suppl 2():16-20. PubMed ID: 16018827
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Screening: should more biopsies be taken in larger prostates?
    van Leeuwen P, van den Bergh R, Wolters T, Schröder F, Roobol M.
    BJU Int; 2009 Oct; 104(7):919-24. PubMed ID: 19466943
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
    Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH.
    Cancer; 2006 Dec 15; 107(12):2779-85. PubMed ID: 17109445
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
    Urology; 2006 Aug 15; 68(2):342-7. PubMed ID: 16904449
    [Abstract] [Full Text] [Related]

  • 33. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E.
    J Urol; 2003 May 15; 169(5):1720-3. PubMed ID: 12686817
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D.
    J Urol; 2007 Nov 15; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
    Punglia RS, Cullen J, McLeod DG, Chen Y, D'Amico AV.
    Cancer; 2007 Nov 01; 110(9):1973-8. PubMed ID: 17886252
    [Abstract] [Full Text] [Related]

  • 38. Interval cancers in the Antwerp European randomised study of screening for prostate cancer study, using a 6 year screening interval.
    Nelen V, Thys G, Hermans A, D'Hooge K, Dourcy-Belle-Rose B, Coebergh JW, Roobol M, Denis L.
    Eur J Cancer; 2010 Nov 01; 46(17):3090-4. PubMed ID: 21047591
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.